Clinicopathological and prognostic significance of FoxM1 in gastric cancer: A meta-analysis

Jiang, Dongdong; Jiang, Lu; Liu, Baiying; Huang, He; Li, Wenbin; Zhang, Taotao; Zu, Guo; Zhang, Xiangwen

doi:10.1016/j.ijsu.2017.09.076

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric cancer is the second most significant reason for global cancer-related mortalities [44], [45] and the fifth most prevalent cancer in the world [46], [47]. In the United States, there are about 7.4 new cases of gastric cancer per 100,000 women and men per year [48].…”

Section: The Role Of Pirnas In Cancermentioning

confidence: 99%

Biological function and molecular mechanism of piRNA in cancer

Chalbatani

Dana

Memari

et al. 2019

Practical Laboratory Medicine

View full text Add to dashboard Cite

Cancer is the second leading cause of death globally. piRNAs, which are a novel type of identified small noncoding RNA (ncRNA), play a crucial role in cancer genomics. In recent years, a relatively large number of studies have demonstrated that several piRNA are aberrantly expressed in various kinds of cancers including gastric cancer, bladder cancer, breast cancer, colorectal cancer and Lung cancer and may probably serve as a novel therapeutic target and biomarker for cancer treatment. The present review summarized current advances in our knowledge of the roles of piRNAs in cancer.

show abstract

Section: The Role Of Pirnas In Cancermentioning

confidence: 99%

Biological function and molecular mechanism of piRNA in cancer

Chalbatani

Dana

Memari

et al. 2019

Practical Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…19,47,48 The first meta-analysis included eight studies involving 529 patients with gastric cancer. 47 The meta-analysis demonstrated that the levels of FOXM1 were associated with TNM stage (odds ratio [OR] ¼ 0.482; 95% CI 0.275, 0.845; P ¼ 0.011), depth of invasion (OR ¼ 0.617; 95% CI 0.382, 0.998; P ¼ 0.049), lymph node metastasis (OR ¼ 2.084; 95% CI 1.305, 3.328; P ¼ 0.002) and 5-year overall survival (OR ¼ 0.180; 95% CI 0.095, 0.341; P < 0.001). 47 Another meta-analysis studied the prognostic value of FOXC1 in various cancers from 16 studies and demonstrated a statistically significant association between FOXC1 protein levels and survival (HR ¼ 1.186; 95% CI 1.122, 1.255; P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…45,46 Three previous systematic reviews have outlined the relationship between levels of the FOX family members and outcomes in multiple cancer types. 19,47,48 The first meta-analysis included eight studies involving 529 patients with gastric cancer. 47 The meta-analysis demonstrated that the levels of FOXM1 were associated with TNM stage (odds ratio [OR] = 0.482; 95% CI 0.275, 0.845; P = 0.011), depth of invasion (OR = 0.617; 95% CI 0.382, 0.998; P = 0.049), lymph node metastasis (OR = 2.084; 95% CI 1.305, 3.328; P = 0.002) and 5-year overall survival (OR = 0.180; 95% CI 0.095, 0.341; P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

Forkhead box F2 as a novel prognostic biomarker and potential therapeutic target in human cancers prone to bone metastasis: a meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective To undertake a systematic review and meta-analysis to evaluate the prognostic value of Forkhead box F2 (FOXF2) levels in different types of cancers prone to bone metastasis. Methods A systematic search of publications listed in electronic databases (The Web of Science, EMBASE®, PubMed®, PMC, Science Direct and CNKI) from inception to 5 November 2020 was conducted. The hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between FOXF2 levels and patient prognosis including overall survival (OS) and disease-free survival (DFS). Results Sixteen studies enrolling 8461 participants were included in the meta-analysis. High levels of FOXF2 were a predictor of OS (HR: 0.66; 95% CI 0.51, 0.86) and DFS (HR: 0.60; 95% CI 0.48, 0.76). The trim-and-fill analysis, sensitivity analysis and subgroup analyses stratified by the study characteristics confirmed the robustness of the results. Conclusion These current findings indicate that high FOXF2 levels could be an indicator of a good prognosis in cancer patients with tumours that are prone to bone metastasis. FOXF2 levels might be a clinically important prognostic biomarker.

show abstract

“…In addition, FoxO1 can promote lipolysis by upregulating the expression of fatty triglyceride lipase. 50 FoxM1 is indispensable for normal cell proliferation, highly expressed in many cancers 51 , 52 , 53 and closely associated with poor prognosis. One of the mechanisms by which FoxM1 promotes tumor development is the reprogramming process of cell metabolism.…”

Section: Drivers Of Metabolic Reprogramming: Related Genes Proteins A...mentioning

confidence: 99%

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Nong

Han

et al. 2023

MedComm

View full text Add to dashboard Cite

Cancer cells characterized by uncontrolled growth and proliferation require altered metabolic processes to maintain this characteristic. Metabolic reprogramming is a process mediated by various factors, including oncogenes, tumor suppressor genes, changes in growth factors, and tumor–host cell interactions, which help to meet the needs of cancer cell anabolism and promote tumor development. Metabolic reprogramming in tumor cells is dynamically variable, depending on the tumor type and microenvironment, and reprogramming involves multiple metabolic pathways. These metabolic pathways have complex mechanisms and involve the coordination of various signaling molecules, proteins, and enzymes, which increases the resistance of tumor cells to traditional antitumor therapies. With the development of cancer therapies, metabolic reprogramming has been recognized as a new therapeutic target for metabolic changes in tumor cells. Therefore, understanding how multiple metabolic pathways in cancer cells change can provide a reference for the development of new therapies for tumor treatment. Here, we systemically reviewed the metabolic changes and their alteration factors, together with the current tumor regulation treatments and other possible treatments that are still under investigation. Continuous efforts are needed to further explore the mechanism of cancer metabolism reprogramming and corresponding metabolic treatments.

show abstract

Clinicopathological and prognostic significance of FoxM1 in gastric cancer: A meta-analysis

Abstract: Expression of FoxM1 is associated with TNM stage, depth of invasion, lymph node metastasis and poor prognosis of the patients with GC.

Cited by 9 publications

References 16 publications

Biological function and molecular mechanism of piRNA in cancer

Biological function and molecular mechanism of piRNA in cancer

Forkhead box F2 as a novel prognostic biomarker and potential therapeutic target in human cancers prone to bone metastasis: a meta-analysis

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Contact Info

Product

Resources

About